Therapeutic implications of fibroblast growth factor receptor inhibitors in a combination regimen for solid tumors (Review)

  • Authors:
    • Hong Luo
    • Tao Zhang
    • Peng Cheng
    • Dong Li
    • Oleksandr Ogorodniitchouk
    • Chaimaa Lahmamssi
    • Ge Wang
    • Meiling Lan
  • View Affiliations

  • Published online on: July 10, 2020     https://doi.org/10.3892/ol.2020.11858
  • Pages: 2525-2536
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

A number of novel drugs targeting the fibroblast growth factor receptor (FGFR) signaling pathway have been developed, including mostly tyrosine kinase inhibitors, selective inhibitors or monoclonal antibodies. Multiple preclinical and clinical studies have been conducted worldwide to ascertain their effects on diverse solid tumors. Drugs, such as lenvatinib, dovitinib and other non‑specific FGFR inhibitors, widely used in clinical practice, have been approved by the Food and Drug Administration for cancer therapy, although the majority of drugs remain in preclinical tests or clinical research. The resistance to a single agent for FGFR inhibition with synthetic lethal action may be overcome by a combination of therapeutic approaches and FGFR inhibitors, which could also enhance the sensitivity to other therapeutics. Therefore, the aim of the present review is to describe the pharmacological characteristics of FGFR inhibitors that may be combined with other therapeutic agents and the preclinical data supporting their combination. Additionally, their clinical implications and the remaining challenges for FGFR inhibitor combination regimens are discussed.

Related Articles

Journal Cover

September-2020
Volume 20 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Luo H, Zhang T, Cheng P, Li D, Ogorodniitchouk O, Lahmamssi C, Wang G and Lan M: Therapeutic implications of fibroblast growth factor receptor inhibitors in a combination regimen for solid tumors (Review). Oncol Lett 20: 2525-2536, 2020
APA
Luo, H., Zhang, T., Cheng, P., Li, D., Ogorodniitchouk, O., Lahmamssi, C. ... Lan, M. (2020). Therapeutic implications of fibroblast growth factor receptor inhibitors in a combination regimen for solid tumors (Review). Oncology Letters, 20, 2525-2536. https://doi.org/10.3892/ol.2020.11858
MLA
Luo, H., Zhang, T., Cheng, P., Li, D., Ogorodniitchouk, O., Lahmamssi, C., Wang, G., Lan, M."Therapeutic implications of fibroblast growth factor receptor inhibitors in a combination regimen for solid tumors (Review)". Oncology Letters 20.3 (2020): 2525-2536.
Chicago
Luo, H., Zhang, T., Cheng, P., Li, D., Ogorodniitchouk, O., Lahmamssi, C., Wang, G., Lan, M."Therapeutic implications of fibroblast growth factor receptor inhibitors in a combination regimen for solid tumors (Review)". Oncology Letters 20, no. 3 (2020): 2525-2536. https://doi.org/10.3892/ol.2020.11858